Tillotts to buy non-US rights of AstraZeneca’s gastroenterology drug Entocort for $250m
Entocort (budesonide) is currently approved in more than 40 countries to treat Crohn’s disease (CD) and ulcerative colitis (UC). The US rights of Entocort will remain with AstraZeneca,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.